Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B.

Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. doi: 10.1111/dom.13811. Epub 2019 Jun 30. Review.

PMID:
31183975
2.

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Leiter LA, Bain SC, Hramiak I, Jódar E, Madsbad S, Gondolf T, Hansen T, Holst I, Lingvay I.

Cardiovasc Diabetol. 2019 Jun 6;18(1):73. doi: 10.1186/s12933-019-0871-8.

3.

Closing the Gap: Results of the Multicenter Canadian Randomized Controlled Trial of Structured Transition in Young Adults With Type 1 Diabetes.

Spaic T, Robinson T, Goldbloom E, Gallego P, Hramiak I, Lawson ML, Malcolm J, Mahon J, Morrison D, Parikh A, Simone A, Stein R, Uvarov A, Clarson C; JDRF Canadian Clinical Trial CCTN1102 Study Group.

Diabetes Care. 2019 Jun;42(6):1018-1026. doi: 10.2337/dc18-2187. Epub 2019 Apr 22.

PMID:
31010873
4.

Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.

Senior P, Hramiak I.

Can J Diabetes. 2019 Oct;43(7):515-523. doi: 10.1016/j.jcjd.2019.01.004. Epub 2019 Jan 24. Review.

5.

GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.

Rodbard HW, Bellary S, Hramiak I, Seino Y, Silver R, Damgaard LH, Nayak G, Zacho J, Aroda VR.

Endocr Pract. 2019 Jun;25(6):589-597. doi: 10.4158/EP-2018-0444. Epub 2019 Mar 13.

PMID:
30865526
6.

Progression of glucose-lowering diabetes therapy in TECOS.

Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group.

Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan.

7.

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.

Pettus J, Roussel R, Liz Zhou F, Bosnyak Z, Westerbacka J, Berria R, Jimenez J, Eliasson B, Hramiak I, Bailey T, Meneghini L.

Diabetes Ther. 2019 Apr;10(2):617-633. doi: 10.1007/s13300-019-0568-8. Epub 2019 Feb 14.

8.

Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement.

Leiter LA, Cheng AYY, Ekoé JM, Goldenberg RM, Harris SB, Hramiak IM, Khunti K, Lin PJ, Richard JF, Senior PA, Yale JF, Goldin L, Tan MK, Langer A.

Can J Diabetes. 2019 Aug;43(6):384-391. doi: 10.1016/j.jcjd.2018.10.005. Epub 2018 Nov 2.

PMID:
30554985
9.

Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons.

Mauricio D, Hramiak I.

Eur Endocrinol. 2018 May;14(Suppl1):2-9. doi: 10.17925/EE.2018.14supp1.2. Epub 2018 May 11. Review.

10.

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Oct;20(10):2379-2388. doi: 10.1111/dom.13377. Epub 2018 Jun 19.

PMID:
29923323
11.

A randomised trial of non-mydriatic ultra-wide field retinal imaging versus usual care to screen for diabetic eye disease: rationale and protocol for the Clearsight trial.

Liu SL, Mahon LW, Klar NS, Schulz DC, Gonder JR, Hramiak IM, Mahon JL.

BMJ Open. 2017 Aug 3;7(8):e015382. doi: 10.1136/bmjopen-2016-015382.

12.

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.

Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. doi: 10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11. Erratum in: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5. Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

13.

Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.

Spaic T, Driscoll M, Raghinaru D, Buckingham BA, Wilson DM, Clinton P, Chase HP, Maahs DM, Forlenza GP, Jost E, Hramiak I, Paul T, Bequette BW, Cameron F, Beck RW, Kollman C, Lum JW, Ly TT; In-Home Closed-Loop (IHCL) Study Group.

Diabetes Care. 2017 Mar;40(3):359-366. doi: 10.2337/dc16-1794. Epub 2017 Jan 18.

14.

Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.

Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, E Klein B, Klein R, Ooi TC, Rossing P, Sattar N, Stehouwer CD, Colhoun HM; REMOVAL Trial Team.

Diabetes Obes Metab. 2017 Apr;19(4):509-516. doi: 10.1111/dom.12840. Epub 2017 Feb 17.

15.

Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.

Calhoun PM, Buckingham BA, Maahs DM, Hramiak I, Wilson DM, Aye T, Clinton P, Chase P, Messer L, Kollman C, Beck RW, Lum J; In Home Closed Loop Study Group.

J Diabetes Sci Technol. 2016 Nov 1;10(6):1216-1221. Print 2016 Nov. Erratum in: J Diabetes Sci Technol. 2017 Mar;11(2):NP1.

16.

Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension.

Wadwa RP, Chase HP, Raghinaru D, Buckingham BA, Hramiak I, Maahs DM, Messer L, Ly T, Aye T, Clinton P, Kollman C, Beck RW, Lum J; In Home Closed Loop Study Group.

Pediatr Diabetes. 2017 Sep;18(6):422-427. doi: 10.1111/pedi.12410. Epub 2016 Jul 12.

17.

In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes.

Messer LH, Calhoun P, Buckingham B, Wilson DM, Hramiak I, Ly TT, Driscoll M, Clinton P, Maahs DM; In Home Closed Loop Study Group.

Pediatr Diabetes. 2017 Aug;18(5):332-339. doi: 10.1111/pedi.12395. Epub 2016 Apr 29.

18.

The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide.

Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX.

Can J Diabetes. 2015 Nov;39 Suppl 4:32-40. doi: 10.1016/j.jcjd.2015.09.087.

PMID:
26541489
19.

Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia.

Rowe BH, Singh M, Villa-Roel C, Leiter LA, Hramiak I, Edmonds ML, Lang E, Sivilotti M, Scheuermeyer F, Worster A, Riley J, Afilalo M, Stiell I, Yale JF, Woo VC, Campbell S; Canadian Association of Emergency Physicians Research Consortium.

Can J Diabetes. 2015 Nov;39 Suppl 4:9-18. doi: 10.1016/j.jcjd.2015.09.084.

PMID:
26541486
20.

The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study.

Clemens KK, McArthur E, Fleet JL, Hramiak I, Garg AX.

CMAJ Open. 2015 Apr 2;3(2):E172-81. doi: 10.9778/cmajo.20140060. eCollection 2015 Apr-Jun.

21.

Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013.

Clemens KK, Shariff S, Liu K, Hramiak I, Mahon JL, McArthur E, Garg AX.

PLoS One. 2015 Sep 3;10(9):e0137596. doi: 10.1371/journal.pone.0137596. eCollection 2015.

22.

Erratum. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. Diabetes Care 2015;38:1197-1204.

Buckingham BA, Raghinaru D, Cameron F, Bequette BW, Chase HP, Maahs DM, Slover R, Wadwa RP, Wilson DM, Ly T, Aye T, Hramiak I, Clarson C, Stein R, Gallego PH, Lum J, Sibayan J, Kollman C, Beck RW; In Home Closed Loop Study Group.

Diabetes Care. 2015 Sep;38(9):1813. doi: 10.2337/dc15-er09. No abstract available.

23.

Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis.

Buckingham BA, Raghinaru D, Cameron F, Bequette BW, Chase HP, Maahs DM, Slover R, Wadwa RP, Wilson DM, Ly T, Aye T, Hramiak I, Clarson C, Stein R, Gallego PH, Lum J, Sibayan J, Kollman C, Beck RW; In Home Closed Loop Study Group.

Diabetes Care. 2015 Jul;38(7):1197-204. doi: 10.2337/dc14-3053. Epub 2015 Jun 6. Erratum in: Diabetes Care. 2015 Sep;38(9):1813.

24.

The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.

Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX.

Can J Diabetes. 2015 Aug;39(4):308-16. doi: 10.1016/j.jcjd.2015.01.001. Epub 2015 Mar 31.

PMID:
25840942
25.

Factors associated with nocturnal hypoglycemia in at-risk adolescents and young adults with type 1 diabetes.

Wilson DM, Calhoun PM, Maahs DM, Chase HP, Messer L, Buckingham BA, Aye T, Clinton PK, Hramiak I, Kollman C, Beck RW; In Home Closed Loop Study Group.

Diabetes Technol Ther. 2015 Jun;17(6):385-91. doi: 10.1089/dia.2014.0342. Epub 2015 Mar 11.

26.

Acute management and outcomes of patients with diabetes mellitus presenting to Canadian emergency departments with hypoglycemia.

Rowe BH, Singh M, Villa-Roel C, Leiter LA, Hramiak I, Edmonds ML, Lang E, Sivilotti M, Scheuermeyer F, Worster A, Riley J, Afilalo M, Stiell I, Yale JF, Woo VC, Campbell S; Canadian Association of Emergency Physicians Research Consortium.

Can J Diabetes. 2015 Feb;39(1):55-64. doi: 10.1016/j.jcjd.2014.04.001. Epub 2014 Aug 29.

PMID:
25175314
27.

Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.

Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC; ACCORD Group of Investigators.

Diabetologia. 2014 Oct;57(10):2030-7. doi: 10.1007/s00125-014-3318-5. Epub 2014 Jul 2.

28.

A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.

Maahs DM, Calhoun P, Buckingham BA, Chase HP, Hramiak I, Lum J, Cameron F, Bequette BW, Aye T, Paul T, Slover R, Wadwa RP, Wilson DM, Kollman C, Beck RW; In Home Closed Loop Study Group.

Diabetes Care. 2014 Jul;37(7):1885-91. doi: 10.2337/dc13-2159. Epub 2014 May 7.

29.

Multicentre randomized controlled trial of structured transition on diabetes care management compared to standard diabetes care in adolescents and young adults with type 1 diabetes (Transition Trial).

Spaic T, Mahon JL, Hramiak I, Byers N, Evans K, Robinson T, Lawson ML, Malcolm J, Goldbloom EB, Clarson CL; JDRF Canadian Clinical Trial CCTN1102 Study Group.

BMC Pediatr. 2013 Oct 9;13:163. doi: 10.1186/1471-2431-13-163.

30.

Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals.

Klausmann G, Hramiak I, Qvist M, Mikkelsen KH, Guo X.

Patient Prefer Adherence. 2013 Apr 5;7:285-92. doi: 10.2147/PPA.S41929. Print 2013.

31.

Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group.

Kidney Int. 2012 Mar;81(6):586-94. doi: 10.1038/ki.2011.415. Epub 2011 Dec 14.

32.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group.

Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466.

33.

Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.

Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and ACCORD Research Groups.

Clin Trials. 2009 Oct;6(5):416-29. doi: 10.1177/1740774509344440. Epub 2009 Sep 8.

34.

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.

Diabetologia. 2009 Sep;52(9):1971-3. doi: 10.1007/s00125-009-1452-2. Epub 2009 Jul 16. No abstract available.

35.

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.

Diabetologia. 2009 Sep;52(9):1778-88. doi: 10.1007/s00125-009-1415-7. Epub 2009 Jun 13.

36.

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):80i-89i. Epub 2007 Apr 17.

PMID:
17599428
37.

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E; Obesity Canada Clinical Practice Guidelines Expert Panel.

CMAJ. 2007 Apr 10;176(8):S1-13. Review. No abstract available.

38.

Reduced IFN-alpha secretion by blood dendritic cells in human diabetes.

Summers KL, Marleau AM, Mahon JL, McManus R, Hramiak I, Singh B.

Clin Immunol. 2006 Oct;121(1):81-9. Epub 2006 Jul 21.

PMID:
16859998
39.

Insulin resistance in latent autoimmune diabetes of adulthood.

Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL.

Ann N Y Acad Sci. 2003 Nov;1005:374-7.

PMID:
14679095
40.

Predicting performance on the Royal College of Physicians and Surgeons of Canada internal medicine written examination.

Brill-Edwards P, Evans G, Hamilton P, Hramiak I, Megran D, Schmuck ML, Cole G, Mikhael N, Norman G.

CMAJ. 2001 Nov 13;165(10):1305-7.

41.

Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy.

Hegele RA, Cao H, Anderson CM, Hramiak IM.

J Clin Endocrinol Metab. 2000 Sep;85(9):3431-5.

PMID:
10999845
42.

Glucose turnover and insulin sensitivity in rats with pancreatic islet transplants.

Guan J, Behme MT, Zucker P, Atkison P, Hramiak I, Zhong R, Dupré J.

Diabetes. 1998 Jul;47(7):1020-6.

PMID:
9648823
43.

Factors affecting glucose tolerance in hereditary hemochromatosis.

Hramiak IM, Finegood DT, Adams PC.

Clin Invest Med. 1997 Apr;20(2):110-8.

PMID:
9088667
44.

Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM.

Dupré J, Behme MT, Hramiak IM, McDonald TJ.

Diabetes Care. 1997 Mar;20(3):381-4. No abstract available.

PMID:
9051391
45.

Continued insulin dependence despite normal range insulin sensitivity and insulin connecting peptide levels in a kidney/islet transplant patient.

Atkison PR, Zucker P, Hramiak I, Paul TL, Dupre J, Behme MT, Scharp DW, Lacy PE, Olack BJ, Stiller CR.

Diabetes Care. 1996 Mar;19(3):236-40.

PMID:
8742568
46.

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.

Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ.

Diabetes. 1995 Jun;44(6):626-30.

PMID:
7789625
47.

Parallel regulation of the local vascular and systemic metabolic effects of insulin.

Feldman RD, Hramiak IM, Finegood DT, Behme MT.

J Clin Endocrinol Metab. 1995 May;80(5):1556-9.

PMID:
7744999
48.

Continued insulin dependence despite normal insulin sensitivity and graft insulin secretion in a kidney/islet transplant patient.

Atkison P, Zucker P, Hramiak I, Paul T, McCallum J, Stiller C, Sharp D, Lacy P, Olack B, Finegood D.

Transplant Proc. 1994 Apr;26(2):573. No abstract available.

PMID:
8171560
49.

Canine, human, and rat plasma insulin responses to galanin administration: species response differences.

McDonald TJ, Tu E, Brenner S, Zabel P, Behme M, Panchal C, Hramiak I, Barnett WB, Miller D, Dupré J.

Am J Physiol. 1994 Apr;266(4 Pt 1):E612-7.

PMID:
7513957
50.

Hepatic extraction of insulin after stimulation of secretion with oral glucose or parenteral nutrients.

Dupré J, Behme MT, Hramiak IM, Longo CJ.

Metabolism. 1993 Aug;42(8):921-7.

PMID:
8345813

Supplemental Content

Loading ...
Support Center